Viveve Completes Enrollment in VIVEVE II Trial

Results
could support a marketing application for an expanded U.S. indication for
improvement of sexual function in women

ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has completed enrollment in its VIVEVE II trial, a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth.

“Completion of enrollment in our VIVEVE II sexual function trial represents a tremendous milestone in our Company’s quest to address an enormous unmet medical need for women. An estimated 12-14 million women worldwide suffer from diminished sexual function following vaginal childbirth. If successful, the results of the VIVEVE II trial, utilizing our CMRF technology, may clinically demonstrate that a safe and effective, single session Viveve treatment can provide meaningful benefits to women suffering from this condition,” said Scott Durbin, chief executive officer and director of Viveve. “We look forward to continued progress in the trial and anticipate a final 12-month data read-out at the end of the first quarter of next year.”

About the VIVEVE II Study

VIVEVE II is a randomized, double-blinded, and sham-controlled trial that has enrolled 250 subjects at 19 clinical sites in the United States and Canada. Subjects were randomized in a 1:1 ratio for active and sham treatments.

The primary efficacy endpoint is the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Subjects will also be assessed for safety over the 12 months. The investigational device exemption (IDE) protocol approved by the U.S. Food and Drug Administration (FDA) also includes a variety of secondary and exploratory endpoints that evaluate the efficacy of and improvement in FSFI domain scores for desire, lubrication, orgasm, arousal, satisfaction, and pain.

About Viveve

Viveve Medical, Inc. is a women’s intimate health company committed to advancing new solutions to improve women’s overall well-being and quality of life. The internationally patented Viveve® System incorporates CMRF technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session.

International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth after receiving approval of an IDE application from the FDA in March of 2018. If successful, this trial could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis.

Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence (SUI) in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two trials, if successful, could support marketing applications in the U.S. and additional countries around the world for this new commercial indication.

For more information visit Viveve’s website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations Contacts:
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com

Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media Contact:
Kelly Wakelee
Berry & Company Public Relations
(212) 253-8881
kwakelee@berrypr.com

SOURCE: Viveve Medical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/538558/Viveve-Completes-Enrollment-in-VIVEVE-II-Trial